DENTSPLY SIRONA - XRAY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $39.50
  • Forecasted Upside: 29.76%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$30.44
▲ +0.08 (0.26%)

This chart shows the closing price for XRAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DENTSPLY SIRONA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XRAY

Analyst Price Target is $39.50
▲ +29.76% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for DENTSPLY SIRONA in the last 3 months. The average price target is $39.50, with a high forecast of $46.00 and a low forecast of $32.00. The average price target represents a 29.76% upside from the last price of $30.44.

This chart shows the closing price for XRAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in DENTSPLY SIRONA. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/26/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/24/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/24/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/23/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/21/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/19/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/19/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$41.00Low
3/1/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$41.00Low
2/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00Low
2/26/2024Leerink PartnrsReiterated RatingOutperformLow
2/26/2024SVB LeerinkInitiated CoverageOutperform$42.00Low
1/12/2024Piper SandlerBoost TargetNeutral ➝ Neutral$31.00 ➝ $35.00Low
1/9/2024Needham & Company LLCBoost TargetBuy ➝ Buy$35.00 ➝ $42.00Low
11/16/2023Needham & Company LLCInitiated CoverageBuy$35.00Low
11/13/2023Stifel NicolausLower TargetHold ➝ Hold$35.00 ➝ $32.00Low
11/10/2023William BlairUpgradeMarket Perform ➝ OutperformLow
11/7/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$42.00 ➝ $36.00Low
11/3/2023Barrington ResearchLower TargetOutperform ➝ Outperform$51.00 ➝ $41.00Low
11/3/2023Morgan StanleyLower TargetOverweight ➝ Overweight$43.00 ➝ $39.00Low
11/1/2023Stifel NicolausLower TargetHold ➝ Hold$41.00 ➝ $35.00Low
10/20/2023Morgan StanleyLower TargetOverweight ➝ Overweight$47.00 ➝ $43.00Low
10/11/2023Evercore ISILower Target$45.00 ➝ $36.00Low
9/22/2023Piper SandlerLower TargetNeutral ➝ Neutral$42.00 ➝ $39.00Low
8/4/2023Barrington ResearchReiterated RatingOutperform$51.00Low
5/5/2023UBS GroupBoost Target$43.00 ➝ $46.00Low
5/4/2023Stifel NicolausBoost Target$37.00 ➝ $41.00Low
5/4/2023Barrington ResearchBoost Target$43.00 ➝ $51.00Low
5/4/2023Robert W. BairdBoost Target$36.00 ➝ $46.00Low
4/19/2023Morgan StanleyBoost TargetOverweight$39.00 ➝ $45.00Low
3/1/2023The Goldman Sachs GroupBoost TargetNeutral$34.00 ➝ $39.00Low
3/1/2023Barrington ResearchBoost Target$40.00 ➝ $43.00Low
2/6/2023Piper SandlerBoost TargetNeutral$29.00 ➝ $35.00Low
1/11/2023William BlairUpgradeUnderperform ➝ Market PerformLow
11/17/2022UBS GroupLower Target$35.00Low
11/17/2022Evercore ISIBoost Target$34.00Low
11/17/2022Robert W. BairdLower Target$32.00Low
11/16/2022The Goldman Sachs GroupLower TargetNeutral$41.00 ➝ $34.00Low
11/15/2022Barrington ResearchLower Target$51.00 ➝ $40.00Low
11/15/2022Morgan StanleyLower TargetOverweight$42.00 ➝ $39.00Low
11/14/2022Piper SandlerLower Target$38.00 ➝ $29.00Low
11/1/2022William BlairReiterated RatingUnderperformLow
10/13/2022Morgan StanleyLower TargetOverweight$44.00 ➝ $42.00Low
8/5/2022William BlairDowngradeMarket Perform ➝ UnderperformLow
7/21/2022The Goldman Sachs GroupLower TargetNeutral$42.00 ➝ $41.00Low
7/20/2022Morgan StanleyLower TargetOverweight$48.00 ➝ $44.00Low
7/11/2022Piper SandlerLower Target$41.00 ➝ $38.00N/A
6/1/2022UBS GroupUpgradeNeutral ➝ Buy$58.00 ➝ $47.00High
5/11/2022Barrington ResearchLower Target$53.00 ➝ $51.00Medium
4/22/2022HC WainwrightLower TargetHold$58.00 ➝ $48.00Medium
4/21/2022The Goldman Sachs GroupLower TargetNeutral$59.00 ➝ $47.00Medium
4/20/2022Morgan StanleyLower TargetOverweight$62.00 ➝ $52.00Low
4/20/2022Barrington ResearchLower Target$72.00 ➝ $53.00High
4/20/2022Piper SandlerReiterated RatingOverweight ➝ Neutral$71.00 ➝ $46.00Medium
4/19/2022Bank of AmericaDowngradeBuy ➝ Neutral$66.00 ➝ $49.00High
4/19/2022William BlairDowngradeOutperform ➝ Market PerformHigh
4/19/2022Robert W. BairdDowngradeOutperform ➝ Neutral$67.00 ➝ $48.00High
3/1/2022The Goldman Sachs GroupLower TargetNeutral$66.00 ➝ $59.00High
3/1/2022Barrington ResearchLower Target$79.00 ➝ $72.00High
3/1/2022Credit Suisse GroupLower TargetOutperform$68.00 ➝ $67.00High
3/1/2022HC WainwrightLower Target$66.00 ➝ $58.00Low
2/18/2022Robert W. BairdLower TargetOutperform$78.00 ➝ $67.00High
1/31/2022Morgan StanleyInitiated CoverageOverweight$62.00Low
8/9/2021HC WainwrightLower TargetNeutral$72.00 ➝ $66.00Low
8/6/2021Barrington ResearchBoost TargetOutperform$77.00 ➝ $79.00Low
5/7/2021Barrington ResearchBoost TargetOutperform$71.00 ➝ $77.00Low
5/7/2021Robert W. BairdBoost TargetOutperform$71.00 ➝ $78.00Medium
5/7/2021HC WainwrightBoost TargetNeutral$60.00 ➝ $72.00Medium
5/6/2021Piper SandlerBoost TargetOverweight$70.00 ➝ $75.00Medium
3/2/2021BarclaysBoost TargetUnderweight$50.00 ➝ $55.00Medium
3/2/2021Robert W. BairdBoost TargetOutperform$62.00 ➝ $71.00Medium
3/2/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$71.00Medium
3/2/2021HC WainwrightReiterated RatingNeutral$55.00 ➝ $60.00Low
3/1/2021Piper SandlerBoost TargetOverweight$63.00 ➝ $70.00Low
1/5/2021Robert W. BairdBoost TargetOutperform$58.00 ➝ $62.00N/A
1/5/2021BarclaysBoost TargetUnderweight$40.00 ➝ $44.00N/A
1/5/2021HC WainwrightBoost TargetNeutral$49.00 ➝ $55.00N/A
12/18/2020Stifel NicolausDowngradeBuy ➝ Hold$52.00Low
12/15/2020Piper SandlerBoost TargetOverweight$51.00 ➝ $61.00High
11/17/2020BarclaysDowngradeEqual Weight ➝ Underweight$40.00Low
11/9/2020HC WainwrightBoost TargetNeutral$45.00 ➝ $49.00High
10/22/2020GuggenheimUpgradeNeutral ➝ BuyHigh
10/5/2020JPMorgan Chase & Co.Boost TargetNeutral$45.00 ➝ $47.00Medium
8/10/2020HC WainwrightLower TargetNeutral$50.00 ➝ $45.00Low
7/20/2020Bank of AmericaBoost TargetBuy$54.00 ➝ $56.00Medium
6/16/2020Piper SandlerInitiated CoverageOverweight$51.00Low
6/15/2020HC WainwrightBoost TargetNeutral$38.00 ➝ $50.00Medium
5/27/2020Evercore ISIUpgradeIn-Line ➝ Outperform$50.00High
5/14/2020CfraLower TargetHold$53.00 ➝ $38.00High
5/11/2020BarclaysLower TargetEqual Weight$42.00 ➝ $40.00High
5/11/2020UBS GroupLower TargetNeutral$59.00 ➝ $44.00High
5/11/2020Barrington ResearchDowngradeOutperform ➝ Market PerformLow
4/24/2020HC WainwrightLower TargetNeutral$51.00 ➝ $38.00Medium
4/19/2020Credit Suisse GroupReiterated RatingBuy$50.00Low
4/19/2020Robert W. BairdUpgradeNeutral ➝ OutperformLow
4/8/2020Robert W. BairdUpgradeNeutral ➝ Outperform$57.00 ➝ $49.00Medium
4/7/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$58.00 ➝ $40.00Medium
4/2/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$66.00Low
3/17/2020JPMorgan Chase & Co.Lower TargetNeutral$65.00 ➝ $45.00High
3/13/2020Stifel NicolausLower TargetBuy$66.00 ➝ $56.00Low
3/11/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyLow
3/3/2020Barrington ResearchLower TargetOutperform$63.00 ➝ $60.00Medium
3/3/2020Robert W. BairdLower TargetNeutral$61.00 ➝ $57.00High
3/3/2020HC WainwrightReiterated RatingNeutral$60.00 ➝ $51.00High
2/19/2020Stifel NicolausBoost TargetBuy$63.00 ➝ $66.00Medium
1/19/2020BarclaysReiterated RatingHold$64.00Medium
12/11/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$65.00Low
11/15/2019HC WainwrightReiterated RatingHold$60.00Low
8/5/2019Barrington ResearchReiterated RatingBuy$63.00High
8/2/2019Wellington ShieldsUpgradeHold ➝ Gradually AccumulateHigh
7/26/2019Evercore ISIInitiated CoverageIn-line ➝ In-LineLow
7/9/2019HC WainwrightReiterated RatingNeutral ➝ Neutral$55.00 ➝ $57.00Low
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
5/6/2019Barrington ResearchUpgradeMarket Perform ➝ Outperform$63.00Medium
5/6/2019HC WainwrightReiterated RatingNeutral ➝ Neutral$49.00 ➝ $55.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/21/2023
  • 12 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/21/2023
  • 6 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
11/20/2023
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2023
  • 12 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2024
  • 16 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2024
  • 20 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/19/2024
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2024

Current Sentiment

  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
DENTSPLY SIRONA logo
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform. It also provides endodontic products consisting of motorized endodontic handpieces, files, sealers, irrigation needles, and other tools that support root canal procedures; restorative products, including dental ceramics, crowns, and veneers; and preventative products, such as curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, and impression materials. In addition, the company offers SureSmile and Byte aligner solutions; VPro/HyperByte, a high-frequency vibration technology device; SureSmile Simulator, which creates a 3D visualization of a patient's outcome; and Byte Plus for treatment planning. Further, it provides dental implants, digital dentures, crown and bridge porcelain products, bone regenerative and restorative solutions, treatment planning software, and educational programs; dental prosthetics; urology catheters; and other health-related consumables. The company serves professional dental and consumable medical device markets through third-party distributors. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina
Read More

Today's Range

Now: $30.44
Low: $30.25
High: $30.68

50 Day Range

MA: $32.84
Low: $30.36
High: $34.13

52 Week Range

Now: $30.44
Low: $26.27
High: $43.24

Volume

1,350,342 shs

Average Volume

3,417,594 shs

Market Capitalization

$6.31 billion

P/E Ratio

N/A

Dividend Yield

2.08%

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of DENTSPLY SIRONA?

The following Wall Street research analysts have issued research reports on DENTSPLY SIRONA in the last twelve months: Barrington Research, Evercore ISI, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, and William Blair.
View the latest analyst ratings for XRAY.

What is the current price target for DENTSPLY SIRONA?

10 Wall Street analysts have set twelve-month price targets for DENTSPLY SIRONA in the last year. Their average twelve-month price target is $39.50, suggesting a possible upside of 29.8%. UBS Group AG has the highest price target set, predicting XRAY will reach $46.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $32.00 for DENTSPLY SIRONA in the next year.
View the latest price targets for XRAY.

What is the current consensus analyst rating for DENTSPLY SIRONA?

DENTSPLY SIRONA currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for XRAY.

What other companies compete with DENTSPLY SIRONA?

How do I contact DENTSPLY SIRONA's investor relations team?

DENTSPLY SIRONA's physical mailing address is 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC, 28277. The medical instruments supplier's listed phone number is (844) 848-0137 and its investor relations email address is [email protected]. The official website for DENTSPLY SIRONA is www.dentsplysirona.com. Learn More about contacing DENTSPLY SIRONA investor relations.